Outcomes Associated With Suicidality in Inpatients With Symptoms of Depression (OASIS-D)
Launched by CHARITE UNIVERSITY, BERLIN, GERMANY · May 26, 2020
Trial Information
Current as of November 14, 2025
Recruiting
Keywords
ClinConnect Summary
The OASIS-D trial is a research study that looks at how depression and suicidal thoughts affect patients who are admitted to the hospital. Over six months, the study will include men and women aged 18 to 75 years who have different levels of depression. Some participants will have been diagnosed with moderate or severe depression and have ongoing suicidal thoughts for at least two days after being admitted. The study aims to better understand their experiences and outcomes during treatment.
To participate, individuals must meet specific criteria, such as having a unipolar depressive episode (a type of depression that doesn't include manic episodes) and, for some groups, showing signs of suicidal thoughts. Participants will need to give their written consent to join the study. Throughout the six months, those involved will be monitored to track their progress and responses to treatment. This trial will help researchers gather important information that can improve care for people with depression and suicidal thoughts in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • For Population 1
- • 1.any form of unipolar depressive episode
- • For Population 2
- • 1. clinical diagnosis of a moderate or severe unipolar depressive episode
- • 2. clinically diagnosed suicidal tendencies that persist for at least 48 hours after admission to hospital
- • 3. Written consent to participate in the study
- • For Population 3
- • 1. Diagnosis of a moderate or severe unipolar depressive disorder through the structured research interview "Mini International Neuropsychiatric Interview" (M.I.N.I.)
- • 2. Suicidality with a value \> / = 1 for item 2 (passive suicidality) OR item 3 (active suicidality) based on the research interview "Sheehan Suicidality Tracking Scale" (S-STS)
- • 3. Written consent to participate in the study
- Exclusion Criteria:
- • Patients younger than 18 years or older than 75 years
- • No clinical diagnosis of a depressive episode
- • Depressive episode in the context of a bipolar disorder- secondary depression as a result of physical illness or substance use
- • severe physical symptoms of disease that make participation in the study impossible
- • Pregnancy
- • not being able to understand the study processes
- • incapable of giving informed consent
- • no authorization to give consent due to (limited) incapacity
About Charite University, Berlin, Germany
Charité - Universitätsmedizin Berlin is a leading academic medical center in Germany, renowned for its commitment to excellence in research, education, and patient care. As one of Europe's largest university hospitals, Charité integrates cutting-edge clinical practices with innovative research initiatives, fostering interdisciplinary collaboration across various medical fields. The institution is dedicated to advancing healthcare through rigorous clinical trials, contributing to the development of new therapies and treatment protocols. With a strong emphasis on translational medicine, Charité aims to bridge the gap between scientific discovery and practical application, ultimately enhancing patient outcomes and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Berlin Mitte, Germany
Patients applied
Trial Officials
Christoph U Correll, MD
Principal Investigator
Charite University, Berlin, Germany
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials